Therefore, this study was designed to determine whether direct intra-tracheal administration of the BK channel activating compounds NS1619 and NS19504 can protect mice against LPS-induced pneumonia, and identify the molecular pathways underlying BK channel activation-mediated protection. This evidence concerns the gene KCNMA1 and pneumonia.